Click here to close now.




















Welcome!

News Feed Item

MediPoint: Biopsy Devices - EU Analysis and Market Forecasts

LONDON, April 22, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:

MediPoint: Biopsy Devices - EU Analysis and Market Forecasts

http://www.reportbuyer.com/pharma_healthcare/diagnostics/medipoint_biopsy_devices_eu_analysis_market_forecasts.html

MediPoint: Biopsy Devices - EU Analysis and Market Forecasts

Summary

Cancer is the uncontrolled growth of abnormal cells in the body. It can affect numerous organs and tissues of the body. When a patient is suspected of having a particular type of cancer, a biopsy procedure is performed to extract a target tissue sample for histological analysis. This intervention typically provides a definitive cancer diagnosis for the patient. Given that these procedures play such an important role in the diagnostic pathway for various cancers, medical device manufacturers have worked to develop biopsy devices that maximize the volume and quality of the tissue samples, as well as decrease their negative impact on the patient's body. As seen with other medical device markets, less invasive biopsy techniques have entered the market and have established a new gold standard in many global regions.

While there are significant barriers facing this market, current and future players can still position themselves to obtain a competitive advantage. The major European countries included in this forecast have general mass screening programs for breast cancer detection and they will be increasing their adoption of more expensive VAB devices. Additionally, the emerging economies will see an increased shift from fine needle aspiration devices to more expensive core biopsy devices over the forecast.

Scope

- An overview of biopsy devices, which includes epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines.
- Annualized EU biopsy devices market revenue and future forecasts from 2010 to 2012, forecast for 7 years to 2019.
- Investigation of current and future market competition for biopsy devices
- Insightful review of the key industry drivers, restraints and challenges as well as predicted impact of key events.
- Competitor assessment including device approval analysis and device sales forecasts.
- Marketed and pipeline product profiles covering efficiency, safety, clinical study details, device approvals, product positioning and device sales forecast.
- Analysis of unmet needs within the market and opportunities for future players.
- Technology trends evaluation to assess strength of pipeline.
- An overview of all devices in development including clinical study details, design and material selection considerations, efficacy reports, and device approval timelines.
- Company profiles including business description, financial overview and SWOT analysis.
- Coverage of key market players.
- Strategic assessment of the biopsy devices sector through market impact analysis, future market scenario and company analysis.
- Direct quotes from Key Opinion Leaders (KOL).

Reasons to buy

- Understand the trends shaping and driving EU biopsy devices Market.
- Realize device preferences of physicians who have performed the tests already.
- Access market sizing, forecasts and quantified growth opportunities in EU biopsy devices market through 2019.
- Quantify candidate patient populations to better design product pricing & launch plans.
- Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape.
- Perform benchmarking analysis of growth opportunities against currently marketed products.
- Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
- Take a comprehensive look at the market's device pipeline and identify promising, paradigm-shifting products.
- Create an effective counter-strategy to gain a competitive advantage against those currently in the market.
- Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for growth.
- What's the next big thing in EU biopsy devices market landscape? Identify, understand and capitalize.
1 Table of Contents
1 Table of Contents 6
1.1 List of Tables 10
1.2 List of Figures 12
2 Introduction 14
2.1 Overview 14
2.2 Catalyst 15
2.3 Related Reports 15
3 Industry Overview 16
3.1 Types of Biopsies 16
3.1.1 Surgical Biopsy 16
3.1.2 Fine Needle Aspiration 16
3.1.3 Core Needle Biopsy 17
3.1.4 Vacuum-Assisted Biopsy 18
3.2 Biopsy Procedure Trends 18
3.2.1 EU 18
3.3 Market Access to Cancer Screening Programs 24
3.3.1 Regulation 24
3.3.2 Biopsy Device Adoption Patterns 27
3.3.3 Reimbursement Trends 31
3.4 Regulatory Issues/Recalls 33
3.5 Mergers & Acquisitions/Key Partnerships 34
3.5.1 Hologic Acquires Suros Surgical Systems 34
3.5.2 C. R. Bard Acquires SenoRx 34
3.5.3 Devicor Medical Products Acquires Breast Care Portfolio from Ethicon Endo-Surgery 34
3.6 Economic Impact of Cancer Screening and Treatment 35
3.7 Additional Indications for Biopsy Devices 36
4 Unmet Needs 37
4.1 Overview 37
4.2 More Efficient Screening Tests for Prostate Cancer 37
4.3 More Efficient Screening Tests for Breast Cancer 38
4.4 More Efficient Screening Guidelines for Thyroid Cancer 38
4.5 Screening Tests That Can Provide Histological Analysis In Situ 39
5 Market Opportunity Analysis 40
5.1 Increase Marketing for Vacuum-Assisted Biopsy Devices in European Countries 40
5.2 Bundling Solutions 41
5.3 Focus Efforts on China's Increasing Adoption of VAB Devices 42
5.4 Market for Prostate Cancer Screening Coverage in Europe 42
6 Market Drivers and Barriers 44
6.1 Market Drivers 44
6.1.1 Inadequate Screening Tests for Particular Cancers 44
6.1.2 Demand for Minimally-Invasive Biopsy Techniques 45
6.1.3 Increased Adherence to Certain Cancer Screening Guidelines 45
6.1.4 Aging Patient Population 46
6.2 Market Barriers 47
6.2.1 Increased Competition from Other Cancer Diagnostic Tests 47
6.2.2 Breast Biopsy Reimbursement Bundling 50
6.2.3 Decreased Adherence to Certain Cancer Screening Guidelines 52
6.2.4 Benefits of Mass Prostate Cancer Screening Being Outweighed by Risks 53
7 Competitive Assessment 55
7.1 Overview 55
7.2 Classification Based on System 55
7.2.1 Vacuum-Assisted Biopsy Devices 55
7.2.2 Core Needle Biopsy Devices 57
7.2.3 Fine Needle Aspiration Devices 58
8 Pipeline Assessment 60
8.1 Overview 60
8.1.1 Optical Biopsy 61
8.1.2 Liquid Biopsy 62
9 Clinical Trial Analysis 63
10 Current and Future Players 65
10.1 Trends in Corporate Strategy 65
10.2 Company Profiles 65
10.2.1 Argon Medical Devices 65
10.2.2 Boston Scientific 68
10.2.3 Cardinal Health 71
10.2.4 CareFusion Corporation 72
10.2.5 Cook Medical 74
10.2.6 C. R. Bard 77
10.2.7 Devicor Medical Products 83
10.2.8 DTR Medical 87
10.2.9 Gallini Medical Devices 88
10.2.10 Hologic 91
10.2.11 INRAD 94
10.2.12 Intact Medical Corporation 96
10.2.13 TSK Laboratory 98
11 Market Outlook 100
11.1 Company Market Share 100
11.1.1 Vacuum-Assisted Biopsy Market Share 100
11.1.2 Core Needle Biopsy/Fine Needle Aspiration Market Share 102
11.2 By Segment 103
11.2.1 Fine Needle Aspiration 103
11.2.2 Core Needle Biopsy 104
11.2.3 Vacuum-Assisted Biopsy 105
11.3 By Geography 106
11.3.1 France 106
11.3.2 Germany 107
11.3.3 Italy 109
11.3.4 Spain 110
11.3.5 United Kingdom 112
12 Appendix 114
12.1 Bibliography 114
12.2 Abbreviations 123
12.3 Report Methodology 125
12.3.1 Overview 125
12.3.2 Coverage 125
12.3.3 Primary Research 125
12.3.4 Secondary Research 126
12.3.5 Forecasting Methodology 127
12.4 Key Opinion Leaders Included in This Study 127
12.5 About the Authors 128
12.5.1 Joseph A. Gregory, Analyst, Surgical Devices 128
12.5.2 Derek Archila, MBA, Director of Research and Analysis, Medical Devices 128
12.6 Global Head of Healthcare 129
12.6.1 Bonnie Bain, Ph.D., Global Head of Healthcare 129
12.7 About MediPoint 130
12.8 About GlobalData 130
12.9 Disclaimer 130

List of Tables

Table 1: Breast Cancer Incidence Rates, 5EU, 2010-2019 21
Table 2: Biopsy Device Adoption Patterns in Diagnosing Prostate Cancer, Global, 2013 and 2019 28
Table 3: Biopsy Device Adoption Patterns in Diagnosing Breast Cancer, Global, 2013 and 2019 29
Table 4: Biopsy Device Adoption Patterns in Diagnosing Lung Cancer, Global, 2013 and 2019 30
Table 5: Biopsy Device Adoption Patterns in Diagnosing Liver Cancer, Global, 2013 and 2019 30
Table 6: Biopsy Device Adoption Patterns in Diagnosing Thyroid Cancer, Global, 2013 and 2019 31
Table 7: Age Demographics, Age >65 Years, Global, 2013 46
Table 8: Stereotactic Breast Biopsy Ambulatory Surgery Center Billing, 2011 51
Table 9: Stereotactic Breast Biopsy Physician Billing, 2011 51
Table 10: Company Profile - Argon Medical Devices 66
Table 11: Product Portfolio - Argon Medical Devices 67
Table 12: Argon Medical Devices, SWOT Analysis, 2013 67
Table 13: Company Profile - Boston Scientific 68
Table 14: Product Portfolio - Boston Scientific 70
Table 15: Boston Scientific SWOT Analysis, 2013 70
Table 16: Company Profile - Cardinal Health 71
Table 17: Product Portfolio - Cardinal Health 72
Table 18: Cardinal Health SWOT Analysis, 2013 72
Table 19: Company Profile - CareFusion Corporation 73
Table 20: Product Portfolio - CareFusion 74
Table 21: CareFusion, SWOT Analysis, 2013 74
Table 22: Company Profile - Cook Medical 75
Table 23: Product Portfolio - Cook Medical 76
Table 24: Cook Medical, SWOT Analysis, 2013 77
Table 25: Company Profile - C. R. Bard 78
Table 26: Product Portfolio - C. R. Bard 78
Table 27: C.R. Bard, SWOT Analysis, 2013 82
Table 28: Company Profile - Devicor Medical Products 83
Table 29: Product Portfolio - Devicor Medical Products 86
Table 30: Devicor Medical Products SWOT Analysis, 2013 86
Table 31: Company Profile - DTR Medical 87
Table 32: Product Portfolio - DTR Medical 87
Table 33: DTR Medical SWOT Analysis, 2013 88
Table 34: Company Profile - Gallini Medical Devices 89
Table 35: Product Portfolio - Gallini Medical Devices 90
Table 36: Gallini Medical Devices SWOT Analysis, 2013 90
Table 37: Company Profile - Hologic 91
Table 38: Product Portfolio - Hologic 93
Table 39: Hologic SWOT Analysis, 2013 93
Table 40: Company Profile - INRAD 94
Table 41: Product Portfolio - INRAD 95
Table 42: INRAD SWOT Analysis, 2013 95
Table 43: Company Profile - Intact Medical Corporation 96
Table 44: Product Portfolio - Intact Medical Corporation 97
Table 45: Intact Medical Corporation SWOT Analysis, 2013 97
Table 46: Company Profile - TSK Laboratory 98
Table 47: Product Portfolio - TSK Laboratory 99
Table 48: TSK Laboratory SWOT Analysis, 2013 99
Table 49: VAB, Global Market Share, 2013 101
Table 50: CNB/FNA, Global Market Share, 2013 102
Table 51: EU FNA Device Sales ($m) Forecast, 2010-2019 103
Table 52: EU CNB Device Sales ($m) Forecast, 2010-2019 104
Table 53: EU VAB Device Sales ($m) Forecast, 2010-2019 105
Table 54: France Biopsy Devices Sales ($m) Forecast, 2010-2019 106
Table 55: Germany Biopsy Devices Sales ($m) Forecast, 2010-2019 108
Table 56: Italy Biopsy Devices Sales ($m) Forecast, 2010-2019 109
Table 57: Spain Biopsy Devices Sales ($m) Forecast, 2010-2019 111
Table 58: United Kingdom Biopsy Devices Sales ($m) Forecast, 2010-2019 112

List of Figures

Figure 1: Biopsy Procedure Volumes: Prostate, 5EU, 2010-2019 19
Figure 2: Biopsy Procedure Volumes: Breast, 5EU, 2010-2019 20
Figure 3: Biopsy Procedure Volumes: Lung, 5EU, 2010-2019 22
Figure 4: Biopsy Procedure Volumes: Liver, 5EU, 2010-2019 23
Figure 5: Biopsy Procedure Volumes: Thyroid, 5EU, 2010-2019 24
Figure 6: EnCor Breast Biopsy System 79
Figure 7: EnCor Enspire Breast Biopsy System 80
Figure 8: EnCor Ultra Breast Biopsy System 80
Figure 9: Finesse Ultra Breast Biopsy System 81
Figure 10: Vacora Breast Biopsy System 82
Figure 11: Original Mammotome System 84
Figure 12: Mammotome Elite 85
Figure 13: Mammotome Revolve 86
Figure 14: VAB, Global Market Share, 2013 101
Figure 15: CNB/FNA, Global Market Share, 2013 102
Figure 16: EU FNA Device Sales ($m) Forecast, 2010-2019 103
Figure 17: EU CNB Device Sales ($m) Forecast, 2010-2019 104
Figure 18: EU VAB Device Sales ($m) Forecast, 2010-2019 105
Figure 19: France Biopsy Devices Sales ($) Forecast, 2010-2019 107
Figure 20: Germany Biopsy Devices Sales ($) Forecast, 2010-2019 108
Figure 21: Italy Biopsy Devices Sales ($) Forecast, 2010-2019 110
Figure 22: Spain Biopsy Devices Sales ($) Forecast, 2010-2019 111
Figure 23: United Kingdom Biopsy Devices Sales ($) Forecast, 2010-2019 113

Read the full report:
MediPoint: Biopsy Devices - EU Analysis and Market Forecasts

http://www.reportbuyer.com/pharma_healthcare/diagnostics/medipoint_biopsy_devices_eu_analysis_market_forecasts.html

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]  
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

SOURCE ReportBuyer

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Whether you like it or not, DevOps is on track for a remarkable alliance with security. The SEC didn’t approve the merger. And your boss hasn’t heard anything about it. Yet, this unruly triumvirate will soon dominate and deliver DevSecOps faster, cheaper, better, and on an unprecedented scale. In his session at DevOps Summit, Frank Bunger, VP of Customer Success at ScriptRock, will discuss how this cathartic moment will propel the DevOps movement from such stuff as dreams are made on to a prac...
SYS-CON Events announced today that DataClear Inc. will exhibit at the 17th International Cloud Expo®, which will take place on November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. The DataClear ‘BlackBox’ is the only solution that moves your PC, browsing and data out of the United States and away from prying (and spying) eyes. Its solution automatically builds you a clean, on-demand, virus free, new virtual cloud based PC outside of the United States, and wipes it clean...
With the proliferation of connected devices underpinning new Internet of Things systems, Brandon Schulz, Director of Luxoft IoT – Retail, will be looking at the transformation of the retail customer experience in brick and mortar stores in his session at @ThingsExpo. Questions he will address include: Will beacons drop to the wayside like QR codes, or be a proximity-based profit driver? How will the customer experience change in stores of all types when everything can be instrumented and a...
Contrary to mainstream media attention, the multiple possibilities of how consumer IoT will transform our everyday lives aren’t the only angle of this headline-gaining trend. There’s a huge opportunity for “industrial IoT” and “Smart Cities” to impact the world in the same capacity – especially during critical situations. For example, a community water dam that needs to release water can leverage embedded critical communications logic to alert the appropriate individuals, on the right device, as...
Manufacturing connected IoT versions of traditional products requires more than multiple deep technology skills. It also requires a shift in mindset, to realize that connected, sensor-enabled “things” act more like services than what we usually think of as products. In his session at @ThingsExpo, David Friedman, CEO and co-founder of Ayla Networks, will discuss how when sensors start generating detailed real-world data about products and how they’re being used, smart manufacturers can use the ...
WebRTC services have already permeated corporate communications in the form of videoconferencing solutions. However, WebRTC has the potential of going beyond and catalyzing a new class of services providing more than calls with capabilities such as mass-scale real-time media broadcasting, enriched and augmented video, person-to-machine and machine-to-machine communications. In his session at @ThingsExpo, Luis Lopez, CEO of Kurento, will introduce the technologies required for implementing thes...
Organizations from small to large are increasingly adopting cloud solutions to deliver essential business services at a much lower cost. According to cyber security experts, the frequency and severity of cyber-attacks are on the rise, causing alarm to businesses and customers across a variety of industries. To defend against exploits like these, a company must adopt a comprehensive security defense strategy that is designed for their business. In 2015, organizations such as United Airlines, Sony...
SYS-CON Events announced today that HPM Networks will exhibit at the 17th International Cloud Expo®, which will take place on November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. For 20 years, HPM Networks has been integrating technology solutions that solve complex business challenges. HPM Networks has designed solutions for both SMB and enterprise customers throughout the San Francisco Bay Area.
Any Ops team trying to support a company in today’s cloud-connected world knows that a new way of thinking is required – one just as dramatic than the shift from Ops to DevOps. The diversity of modern operations requires teams to focus their impact on breadth vs. depth. In his session at DevOps Summit, Adam Serediuk, Director of Operations at xMatters, Inc., will discuss the strategic requirements of evolving from Ops to DevOps, and why modern Operations has begun leveraging the “NoOps” approa...
While many app developers are comfortable building apps for the smartphone, there is a whole new world out there. In his session at @ThingsExpo, Narayan Sainaney, Co-founder and CTO of Mojio, will discuss how the business case for connected car apps is growing and, with open platform companies having already done the heavy lifting, there really is no barrier to entry.
To assist customers with legacy Windows Server 2003 that is no longer supported by Microsoft, Racemi has introduced fixed price packages for upgrading and migrating Windows Server 2003 servers to either Windows 2008 R2 or Windows 2012 R2 and the choice of Amazon Web Services (AWS) or SoftLayer cloud. "We're extending a lifeline by upgrading the legacy servers to more modern Windows Server platforms while taking advantage of cloud computing," said James Strayer, vice president of product managem...
All major researchers estimate there will be tens of billions devices - computers, smartphones, tablets, and sensors - connected to the Internet by 2020. This number will continue to grow at a rapid pace for the next several decades. With major technology companies and startups seriously embracing IoT strategies, now is the perfect time to attend @ThingsExpo, November 3-5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. Learn what is going on, contribute to the discussions, and e...
As more intelligent IoT applications shift into gear, they’re merging into the ever-increasing traffic flow of the Internet. It won’t be long before we experience bottlenecks, as IoT traffic peaks during rush hours. Organizations that are unprepared will find themselves by the side of the road unable to cross back into the fast lane. As billions of new devices begin to communicate and exchange data – will your infrastructure be scalable enough to handle this new interconnected world?
In today's digital world, change is the one constant. Disruptive innovations like cloud, mobility, social media, and the Internet of Things have reshaped the market and set new standards in customer expectations. To remain competitive, businesses must tap the potential of emerging technologies and markets through the rapid release of new products and services. However, the rigid and siloed structures of traditional IT platforms and processes are slowing them down – resulting in lengthy delivery ...
The Internet of Things is in the early stages of mainstream deployment but it promises to unlock value and rapidly transform how organizations manage, operationalize, and monetize their assets. IoT is a complex structure of hardware, sensors, applications, analytics and devices that need to be able to communicate geographically and across all functions. Once the data is collected from numerous endpoints, the challenge then becomes converting it into actionable insight.